Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Ocuphire Pharma logo — Restoring Vision and Clarity

Ocuphire Pharma

Restoring Vision and Clarity

Founded 2018 United States Farmington Hills, United States 15 employees Post-IPO Equity Total: $24.56M Biopharma, Biotechnology +1

General Information

Company Name Ocuphire Pharma
Founded Year 2018
Location United States Farmington Hills, United States
Founders / Decision Makers
Team member
Employees 15
Industries Biopharma, Biotechnology, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Ocuphire Pharma. To contact Ocuphire Pharma, visit ocuphire.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ocuphire Pharma compare?

A PDF of Ocuphire Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ocuphire Pharma soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ocuphire Pharma

Ocuphire Pharma is a late-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for retinal and refractive disorders. Founded in 2018, the company operates in the Biopharma, Biotechnology, and Pharmaceutical industries. With the slogan "Restoring Vision and Clarity," Ocuphire's pipeline currently includes two small-molecule product candidates targeting significant unmet needs. The company recently received a substantial $15.00MPost-IPO Equity investment on 08 June 2021. The investment came from prominent firms including Altium Capital, Lincoln Park Capital Fund, Ayrton Capital, and District 2 Capital. Ocuphire Pharma's innovative approach and financial backing from these respected investors signify a promising future in the ophthalmic biopharmaceutical space.

Business keywords: ophthalmic biopharmaceutical, retinal disorders, refractive disorders, small-molecule product candidates, late-stage, therapy development, commercialization, vision care, drug development, ophthalmology, clinical trials, unmet medical needs

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $15.00M 4
Altium Capital Lincoln Park Capital Fund Ayrton Capital
Altium Capital, Lincoln Park Capital Fund +2
08 Jun 2021
Grant $1.70M 1
National Eye Institute
16 Nov 2020
Venture Round $2.13M -
21 Jan 2020
Seed Round $5.00M 5
Belle Capital Michigan Angel Fund BlueWater Angels
Belle Capital, Michigan Angel Fund +3
22 Jul 2019
Venture Round $734.46K -
05 Jun 2018

Ocuphire Pharma Alternatives & Competitors

View All Alternatives
Ocuphire Pharma vs
Realm Therapeutics, Inc.
Realm Therapeutics, Inc. United States

Realm Therapeutics (AIM: RLM) is a clinical-stage biopharmaceutical company focused on developing no...

Post-IPO Equity
2 employees
Biotechnology, Pharmaceutical
Ocuphire Pharma vs
PaxMedica, Inc.
PaxMedica, Inc. United States

Empowering Possibilities, Transforming Lives: PaxMedica's Journey in Neurodevelopmental Solutions

Post-IPO Equity
7 employees
Biotechnology, Pharmaceutical
Ocuphire Pharma vs
Theratechnologies Inc.
Theratechnologies Inc. Canada

Health innovation that matters | #HIV #NASH #Oncology

Post-IPO Equity
98 employees
Biotechnology, Pharmaceutical
View all alternatives

FAQ About Ocuphire Pharma

Restoring Vision and Clarity
Ocuphire Pharma was founded in 2018.
Ocuphire Pharma is headquartered in Farmington Hills, United States.
Ocuphire Pharma operates in Biopharma, Biotechnology and Pharmaceutical. Its work centres on ophthalmic biopharmaceutical, retinal disorders, refractive disorders and small-molecule product candidates.
Ocuphire Pharma has approximately 15 employees.
Ocuphire Pharma has completed 5 funding rounds, raising a total of $24.56M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Ocuphire Pharma include Realm Therapeutics, Inc., PaxMedica, Inc., Theratechnologies Inc., MediciNova, ORIC Pharmaceuticals Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ocuphire Pharma and Realm Therapeutics, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ocuphire Pharma, https://bouncewatch.com/company/ocuphire-pharma, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes